Harrold van Barlingen
Harrold, managing partner, headed the life sciences effort of AlpInvest Partners managing a portfolio of over 30 companies, prior to founding Thuja Capital in 2006. Harrold joined AlpInvest Partners in 2001, from the Boston Consulting Group (BCG), where he worked as a consultant in management and strategy. Before BCG, he was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an internationally active firm specialized in the field of health economics.
Harrold holds a M.Sc. degree in Medical Biology and a Ph.D. in Medicine, both from Utrecht University. From 1991-1992 he was a visiting scientist at the University of Chicago, USA. He is the author of a wide variety of peer-reviewed scientific and pharmaco-economics papers.
Harrold serves on the supervisory boards of Hemics (chairman), Galapagos (GLPG, Euronext), Encare Biotech and Glucare Diabetes.
Michel, managing partner, joined Thuja Capital early 2008. He has gained broad hands-on as well as strategic experience in a variety of senior management positions both in the international pharmaceutical industry (e.g. Janssen Pharmaceutica (Belgium), Yamanouchi (currently Astellas Pharma)) as well as in the biotech industry (Crucell). Moreover, he worked as a consultant for a number of small pharmaceutical and biotech start-up companies in The Netherlands.
Michel brings a wealth of drug development know-how to the Thuja team, ranging from small molecules to biotech products. Moreover, having been in charge of various drug development programs as a project leader, he understands the complexity of drug development and project management, and has built a large network of specialists.
Michel holds a M.Sc. degree in Pharmacy (Utrecht University) and a Ph.D. in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (Dip.Phar.Med., European Center for Pharmaceutical Sciences, Basle). Michel authored over 25 peer reviewed scientific papers and book chapters on pharmacology and drug development.
Michel is on the supervisory boards of Fabpulous (chairman), NightBalance, Cristal Therapeutics (observer), Mellon Medical, MILabs and Nutrileads.
Florian joined the Thuja Capital management team in 2016. Prior to Thuja Capital, Florian has held management positions along the entire medtech development continuum, from early concept to competitive commercialization. He has led and served on innovation and development teams in global organizations (Guidant, Abbott Vascular, Covidien) and in start-ups (Ventrigraft, Ventrica, ROX Medical, Direct Flow Medical). Drawing on a combination of scientific understanding, market insight and direct field experience, Florian has provided leadership to innovative therapy development programs for cardiopulmonary, cardiovascular, structural heart and orthopedic indications. He has worked, studied and lived in six countries on two continents.
Florian brings extensive medical device expertise to the Thuja team, including an intimate understanding of combination devices. Based on his broad background and experience, he has a comprehensive understanding of market drivers and success factors. Florian has access to a solid network of industry experts and leading physicians.
Florian holds a Diplom and a doctorate degree in physics from the Technical University of Munich, Germany, gained in research collaborations with Duke University, USA, and the University of British Columbia, Canada. He is an author on over 30 issued patents.
Martin, financial controller, has been involved with Thuja since inception in 2007. He has extensive experience with financial management in general and with venture capital in particular (amongst which ABN Amro Private Equity, AAC Life Sciences, Forbion, V-Bio), as well as biotech companies (for example Pharming, Crucell, Uniqure, ProQR Therapeutics). Martin has been an independent financial manager & consultant since 2004. Before that, Martin worked several years as manager and consultant at Arthur Andersen (predecessor of Deloitte) in the field of business process management and as an auditor at EY.